Teijaro Lab

@Teijaro_Lab

Chronic viral infections, Chemical Immunology, and immuno-oncology @ScrippsResearch

La Jolla, San Diego scripps.edu/research/facul… Joined March 2018

244 Following 385 Followers 51 Posts

Latest posts 5

Teijaro Lab @Teijaro_Lab Jun 23, 2024

Congrats to everyone involved. @andyjminn, @EJohnWherry, @divijmathew, @zakjerry1 and @Isa57569543. Two great complimentary studies that hopefully will catalyze better treatments for patients in need soon! 👏

Science Magazine Verified account @ScienceMagazine Jun 20, 2024

In two separate Science studies, researchers report that combining JAK inhibitors with checkpoint inhibitor immunotherapy enhances cancer patient response.

Learn more ⬇️
📄: scim.ag/7p1
📄: scim.ag/7p2
#SciencePerspective: scim.ag/7p0

View quoted post on X

Teijaro Lab @Teijaro_Lab Jun 21, 2024

Proud of my two post-docs on their Science paper demonstrating JAK inhibitors can promote better anti-tumor responses in combination with checkpoint immunotherapy. Well done Jerry and Isa as well as all the authors! Special thanks to Dr. Veronika Bachanova for running the trial!

Scripps Research Verified account @scrippsresearch Jun 21, 2024

A new @ScienceMagazine study led by Prof. John Teijaro, PhD, found that combining ruxolitinib, an approved drug, with checkpoint inhibitors supercharged T-cell responses. This could transform #cancer treatment, especially for tough-to-treat cancers.

More: ow.ly/h7ol50SmP4I

View quoted post on X

Teijaro Lab @Teijaro_Lab Jan 8, 2024

nature.com/articles/s4158…
Pleased to see this one in print. What a journey with the parker lab @_chrisgparker_! Great example of merging chemical biology and immunology to generate an exciting tool to probe the immune response. Congrats to everyone involved and all the hard work!!

Teijaro Lab @Teijaro_Lab Jan 4, 2023

Humbled to be a part of this newest venture with great colleagues Ben Cravatt, Chris Parker and Stuart Schreiber. Looking forward to what lies ahead!

FierceBiotech Verified account @FierceBiotech Jan 4, 2023

Belharra Therapeutics is finally ready to rise out of stealth with $130 million in capital and a multi-year collaboration with Genentech.
fiercebiotech.com/biotech/belhar…
View quoted post on X

Teijaro Lab @Teijaro_Lab Oct 8, 2022

Excited to share work with our lab and Parker lab @_chrisgparker_ on the development and characterization of the first Slc15a4 inhibitors.

biorxiv.org/content/10.110…